Humacyte (NASDAQ:HUMA) Given Neutral Rating at Piper Sandler

Piper Sandler restated their neutral rating on shares of Humacyte (NASDAQ:HUMA) in a report issued on Tuesday morning, Benzinga reports. They currently have a $4.00 price objective on the stock.

Other analysts also recently issued reports about the stock. HC Wainwright initiated coverage on shares of Humacyte in a report on Monday, December 11th. They issued a buy rating and a $6.00 target price on the stock. Benchmark restated a buy rating and issued a $15.00 target price on shares of Humacyte in a report on Monday, March 25th.

Humacyte Stock Up 0.3 %

Shares of HUMA stock opened at $3.11 on Tuesday. The stock has a market cap of $363.43 million, a P/E ratio of -2.91 and a beta of 1.53. Humacyte has a 52 week low of $1.96 and a 52 week high of $5.60. The company has a quick ratio of 6.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.46. The company’s fifty day simple moving average is $3.55 and its two-hundred day simple moving average is $2.98.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Friday, March 22nd. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.01. During the same quarter in the previous year, the firm posted ($0.21) earnings per share. Analysts predict that Humacyte will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Humacyte

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in Humacyte by 13.2% in the 2nd quarter. BlackRock Inc. now owns 4,304,505 shares of the company’s stock worth $12,311,000 after acquiring an additional 501,265 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Humacyte by 3.5% in the 4th quarter. Vanguard Group Inc. now owns 3,123,266 shares of the company’s stock worth $8,870,000 after purchasing an additional 104,299 shares during the period. Geode Capital Management LLC lifted its position in shares of Humacyte by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,101,967 shares of the company’s stock worth $3,152,000 after purchasing an additional 48,034 shares during the period. State Street Corp lifted its position in shares of Humacyte by 57.3% in the 2nd quarter. State Street Corp now owns 1,039,280 shares of the company’s stock worth $2,972,000 after purchasing an additional 378,485 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Humacyte by 9.0% in the 4th quarter. Northern Trust Corp now owns 565,107 shares of the company’s stock worth $1,605,000 after purchasing an additional 46,521 shares during the period. 44.71% of the stock is currently owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).